Iqvia Holdings Inc.

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 11/12/2024 GMT			5-day change	1st Jan Change
201.07 ^USD	-1.05%		-1.03%	-13.10%

12-11	TD Cowen Cuts Price Target on IQVIA Holdings to $250 From $255	MT
12-11	Jefferies Raises Price Target on IQVIA Holdings to $200 From $195	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Iqvia Holdings Inc.

TD Cowen Cuts Price Target on IQVIA Holdings to $250 From $255	12-11	MT
Jefferies Raises Price Target on IQVIA Holdings to $200 From $195	12-11	MT
Baird Trims Price Target on IQVIA Holdings to $212 From $213, Keeps Neutral Rating	12-11	MT
Deutsche Bank Adjusts IQVIA Holdings Price Target to $260 From $265, Maintains Buy Rating	12-11	MT
IQVIA Holdings Inc. - Analyst/Investor Day	12-10
HSBC Adjusts Price Target on IQVIA Holdings to $270 From $290	12-04	MT
Nephron Upgrades IQVIA Holdings to Buy, Price Target is $250	12-02	MT
Nephron Research Upgrades IQVIA to Buy, Price Target is $250	12-02	MT
Goldman Sachs Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Buy Rating	11-26	MT
Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $255 From $276, Maintains Buy Rating	11-25	MT
Baird Adjusts Price Target on IQVIA Holdings to $213 From $223, Maintains Neutral Rating	11-25	MT
Leerink Adjusts Price Target on IQVIA Holdings to $248 From $260, Maintains Outperform Rating	11-19	MT
IQVIA Holdings Inc. Presents at UBS Global Healthcare Conference 2024, Nov-13-2024 10:15 AM	11-13
Argus Cuts Price Target on IQVIA to $260 From $280	11-06	MT
JPMorgan Cuts Price Target on IQVIA to $240 From $279, Maintains Overweight Rating	11-05	MT
UBS Adjusts Price Target on IQVIA to $260 From $300, Maintains Buy Rating	11-01	MT
Citigroup Adjusts Price Target on IQVIA to $225 From $250	11-01	MT
Jefferies Adjusts Price Target on IQVIA to $195 From $242	11-01	MT
BTIG Adjusts Price Target on IQVIA to $260 From $290	11-01	MT
Baird Adjusts Price Target on IQVIA to $223 From $256	11-01	MT
Barclays Adjusts Price Target on IQVIA to $255 From $260	11-01	MT
Goldman Sachs Adjusts Price Target on IQVIA to $250 From $280	11-01	MT
Deutsche Bank Adjusts Price Target on IQVIA to $265 From $270	11-01	MT
Evercore ISI Adjusts Price Target on IQVIA to $235 From $265	11-01	MT
Leerink Partners Adjusts Price Target on IQVIA to $260 From $270	11-01	MT

Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).

Employees

88,000

Sector

Biotechnology & Medical Research

Calendar

11/02/2025 - Q4 2024 Earnings Release (Projected)

More about the company